Novel C-C chemokine receptor 2 antagonists in metabolic disease: a review of recent developments
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Young Sun | - |
dc.contributor.author | Cha, Jin Joo | - |
dc.contributor.author | Hyun, Young Youl | - |
dc.contributor.author | Cha, Dae Ryong | - |
dc.date.accessioned | 2021-09-07T12:02:02Z | - |
dc.date.available | 2021-09-07T12:02:02Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2011-06 | - |
dc.identifier.issn | 1354-3784 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/112338 | - |
dc.description.abstract | Introduction: C-C chemokine ligand 2 (CCL2), also known as monocyte chemoattractant protein-1, and its receptor, C-C chemokine receptor 2 (CCR2), play important roles in various inflammatory diseases. Recently, it has been reported that the CCL2/CCR2 pathway also has an important role in the pathogenesis of metabolic syndrome through its association with obesity and related systemic complications. Areas covered: This review focuses on the roles of CCR2 in the pathogenesis of adipose tissue inflammation and other organ damage associated with metabolic syndrome, which is still a matter of debate in many studies. It also covers the use of novel CCR2 antagonists as therapies in such conditions. Expert opinion: There is abundant experimental evidence that the CCL2/CCR2 pathway may be involved in chronic low-grade inflammation of adipose tissue in obesity and related metabolic diseases. Although animal models of diabetes and obesity, as well as human trials, have produced controversial results, there is continued interest in the roles of CCR2 inhibition in metabolic disease. Further identification of the mechanisms for recruitment and activation of phagocytes and determination of the roles of other chemokines are needed. Future study of these fundamental questions will provide a clearer understanding of adipose tissue biology and potential therapeutic targets for treatment of obesity-related metabolic disease, including diabetic nephropathy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.subject | MONOCYTE CHEMOATTRACTANT PROTEIN-1 | - |
dc.subject | ADIPOSE-TISSUE INFLAMMATION | - |
dc.subject | STREPTOZOTOCIN-TREATED MICE | - |
dc.subject | CULTURED MESANGIAL CELLS | - |
dc.subject | HUMAN ENDOTHELIAL-CELLS | - |
dc.subject | SMOOTH-MUSCLE CELLS | - |
dc.subject | FACTOR-KAPPA-B | - |
dc.subject | INSULIN-RESISTANCE | - |
dc.subject | HEPATIC STEATOSIS | - |
dc.subject | CCR2B RECEPTOR | - |
dc.title | Novel C-C chemokine receptor 2 antagonists in metabolic disease: a review of recent developments | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kang, Young Sun | - |
dc.contributor.affiliatedAuthor | Cha, Jin Joo | - |
dc.contributor.affiliatedAuthor | Cha, Dae Ryong | - |
dc.identifier.doi | 10.1517/13543784.2011.575359 | - |
dc.identifier.scopusid | 2-s2.0-79955830809 | - |
dc.identifier.wosid | 000290488100004 | - |
dc.identifier.bibliographicCitation | EXPERT OPINION ON INVESTIGATIONAL DRUGS, v.20, no.6, pp.745 - 756 | - |
dc.relation.isPartOf | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - |
dc.citation.title | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - |
dc.citation.volume | 20 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 745 | - |
dc.citation.endPage | 756 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | MONOCYTE CHEMOATTRACTANT PROTEIN-1 | - |
dc.subject.keywordPlus | ADIPOSE-TISSUE INFLAMMATION | - |
dc.subject.keywordPlus | STREPTOZOTOCIN-TREATED MICE | - |
dc.subject.keywordPlus | CULTURED MESANGIAL CELLS | - |
dc.subject.keywordPlus | HUMAN ENDOTHELIAL-CELLS | - |
dc.subject.keywordPlus | SMOOTH-MUSCLE CELLS | - |
dc.subject.keywordPlus | FACTOR-KAPPA-B | - |
dc.subject.keywordPlus | INSULIN-RESISTANCE | - |
dc.subject.keywordPlus | HEPATIC STEATOSIS | - |
dc.subject.keywordPlus | CCR2B RECEPTOR | - |
dc.subject.keywordAuthor | adipose tissue macrophage | - |
dc.subject.keywordAuthor | CCR2 antagonist | - |
dc.subject.keywordAuthor | chemokine ligand 2 | - |
dc.subject.keywordAuthor | chemokine receptor 2 | - |
dc.subject.keywordAuthor | diabetic nephropathy | - |
dc.subject.keywordAuthor | insulin resistance | - |
dc.subject.keywordAuthor | metabolic syndrome | - |
dc.subject.keywordAuthor | obesity | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.